perinat
transmiss
hiv
women
famili
counsel
schedul
care
visit
diagnost
test
hiv
chemoprophylaxi
zidovudin
zdv
trimethoprimsulfamethoxazol
tmpsmx
recommend
atrisk
infant
tabl
dna
polymeras
chain
reaction
detect
hiv
recommend
hospit
discharg
diagnost
test
hiv
infant
detect
infect
infant
birth
diagnos
month
age
physician
follow
infant
close
first
sever
month
life
mother
counsel
breastfeed
infant
addit
risk
transmiss
hiv
author
institut
first
postnat
visit
done
day
life
visit
complianc
zdv
regimen
assess
dose
adjust
need
refil
given
ensur
infant
suppli
zdv
also
feed
practic
nutritionar
discuss
complet
blood
count
recommend
monitor
hematolog
toxic
commonli
anemia
leukopenia
hiv
dna
pcr
done
birth
perform
visit
second
visit
week
age
zdv
discontinu
hiv
dna
pcr
test
neg
visit
complet
blood
count
tcell
subset
dna
hiv
pcr
result
obtain
tmpsmx
begun
dose
dose
given
three
time
week
prophylaxi
pneumocysti
curinii
pneumonia
pcp
first
set
immun
given
pcp
prophylaxi
start
empir
atrisk
infant
less
year
age
independ
cell
count
percentag
hiv
statu
may
uncertain
infect
infant
rapid
pronress
diseas
cell
count
decreas
precipit
thifirsi
k
h
life
predispos
pcprn
atrisk
infant
seen
month
age
routin
care
immun
appropri
immun
diagnost
test
atrisk
infant
two
neg
hiv
dna
pcr
test
result
month
age
clinic
immunolog
normal
pcp
prophylaxi
discontinu
children
consid
presumpt
hiv
neg
hiv
enzymelink
immunosorb
assay
test
perform
year
age
monitor
disappear
matern
antibodi
hiv
enzymelink
immunosorb
assay
western
blot
neg
elisa
test
repeat
result
neg
child
consid
uninfect
serorevert
mani
infant
born
hivinfect
women
receiv
combin
antiretrovir
therapi
physician
care
note
drug
exposur
infant
chart
maintain
followup
long
possibl
determin
longterm
effect
prenat
postnat
exposur
drug
also
congenit
anomali
unusu
ill
occur
infant
systemat
approach
children
hiv
infect
essenti
children
assess
symptom
relat
hiv
need
treatment
prophylaxi
opportunist
infect
hivrel
condit
baselin
laboratori
test
perform
assess
viral
immunolog
statu
complet
medic
immun
histori
obtain
particular
emphasi
mode
transmiss
exposur
antiretrovir
agent
gestat
deliveri
time
diagnosi
hiv
famili
member
awar
diagnosi
level
understand
hiv
assess
children
caregiv
clinic
trial
avail
discuss
children
famili
children
hiv
receiv
routin
pediatr
care
monitor
hiv
diseas
statu
expert
recommend
hivinfect
children
consult
hiv
specialist
case
pediatrician
provid
routin
care
referr
hiv
specialist
monitor
hiv
statu
wherea
care
set
hiv
specialist
provid
primari
specialti
care
hivinfect
children
seen
least
everi
month
visit
complet
physic
examin
done
attent
sign
symptom
commonli
associ
hiv
infect
growth
develop
evalu
stage
develop
adolesc
medic
review
dose
adjust
growth
complianc
assess
children
assign
classif
tabl
laboratori
studi
done
monitor
immunolog
virolog
statu
diseas
hiv
infect
multisystem
ill
common
clinic
manifest
pediatr
hiv
infect
includ
gener
lymphadenopathi
hepatomegali
splenomegali
oral
candidiasi
parot
recurr
persist
diarrhea
failur
thrive
development
delay
multipl
organ
system
involv
common
follow
hivassoci
condit
found
cardiomyopathi
lymphoid
interstiti
pneumon
nephropathi
encephalopathi
enteropathi
hepat
malign
skin
manifest
caus
bacteri
viral
fungal
infect
atop
diseas
hypersensit
reaction
prurit
papular
reaction
common
tabl
outlin
clinic
laboratori
studi
assess
done
baselin
thereaft
period
interv
studi
done
identifi
e
problem
assess
risk
opportunist
infect
hivrel
complic
monitor
medic
side
effect
studi
shown
prognosi
children
relat
independ
viral
burden
immun
also
direct
relationship
exist
develop
certain
opportunist
infect
degre
immun
suppress
hivinfect
children
baselin
antibodi
titer
obtain
toxoplasma
cytomegaloviru
cmv
epsteinbarr
viru
varicellazost
viru
herp
simplex
viru
hsv
hepat
virus
result
provid
inform
children
exposur
suscept
specif
infect
exampl
cmvseroneg
child
requir
blood
transfus
cmvneg
donor
blood
request
unavail
leukofilt
blood
use
year
follow
test
servic
perform
hivinfect
children
chest
radiographi
test
identifi
mediastin
enlarg
lung
lesion
lymphoid
interstiti
pneumon
lip
cardiomegali
patient
chronic
lung
diseas
oxygen
satur
read
perform
everi
visit
baselin
plain
brain
ct
scan
may
show
chang
basal
ganglia
calcif
brain
regularstrength
tuberculin
skin
test
done
yearli
child
live
area
endem
tuberculosi
hivinfect
children
increas
risk
tuberculosi
control
anergi
candida
mump
tetanu
toxoid
use
depend
child
age
immun
statu
visual
screen
children
capabl
cooper
examin
ophthalmolog
examin
perform
year
children
immun
categori
need
examin
ophthalmologist
everi
month
especi
seroposit
toxoplasmosi
cmv
high
risk
retin
psychometr
test
children
suspect
development
delay
loss
acquir
mileston
identifi
problem
treat
gynecolog
examin
femal
adolesc
refer
adolesc
gynecologist
adolesc
servic
baselin
annual
gynecolog
visit
provid
femal
adolesc
sexual
activ
cervic
smear
screen
sexual
transmit
diseas
adolesc
awar
diagnos
receiv
counsel
regard
transmiss
hiv
safe
sex
practic
birth
control
risk
referr
specialti
servic
depend
medic
statu
patient
ideal
specialist
particip
care
children
awar
problem
affect
hivinfect
children
maintain
commun
primari
care
physician
care
hivinfect
children
complex
children
caregiv
readi
access
health
care
provid
discuss
medic
problem
coordin
familycent
comprehens
care
team
physician
nurs
case
manag
social
worker
facilit
treatment
patient
work
caregiv
author
program
case
manag
social
worker
assign
patient
provid
commun
referr
social
servic
psychosoci
intervent
home
health
agenc
provid
administr
parenter
medic
home
well
instruct
supervis
regard
medic
fostercar
system
essenti
meet
need
atrisk
infant
abandon
protect
custodi
hivinfect
children
lost
parent
caregiv
prescrib
day
care
provid
nurs
servic
import
care
sever
ill
medic
complex
children
hiv
assess
growth
integr
part
care
pediatr
patient
hivinfect
children
care
monitor
height
weight
head
circumfer
infanc
childhood
evalu
pubert
chang
growth
adolesc
sever
measur
growth
use
infant
children
includ
standard
growth
chart
increment
growth
curv
computer
calcul
z
score
use
epi
info
version
center
diseas
control
prevent
growth
delay
common
hivinfect
infant
first
sign
symptomat
hiv
infect
end
spectrum
diseas
weight
loss
wast
may
occur
older
children
adolesc
progress
hiv
diseas
basal
metabol
children
hnt
infect
increas
compar
noninfect
children
stress
calor
need
increas
averag
degre
celau
increas
temperatur
acut
diarrhea
children
growth
delay
wast
evalu
done
determin
potenti
caus
goal
treat
caus
growth
failur
weight
loss
estim
energi
need
children
grow
follow
formula
use
estim
energi
need
children
need
catchup
growth
period
rda
kcal
weight
age
x
ideal
weight
age
actual
weight
kcal
kg
rda
recommend
daili
allow
weight
age
weight
patient
present
weight
would
percentil
use
laboratori
paramet
assess
nutrit
statu
includ
albumin
assess
longterm
viscer
protein
prealbumin
assess
shortterm
viscer
protein
iron
vitamin
b
folat
studi
micronutri
ie
zinc
magnesium
selenium
copper
carnitin
vitamin
level
manag
nutrit
defici
children
may
includ
one
follow
intervent
dietari
instruct
vitamin
supplement
highcalori
formula
aliment
use
nasogastr
tube
intraven
iv
hyperaliment
nutritionist
invalu
assist
medic
team
dietari
histori
energi
intak
recommend
appropri
intervent
sever
highenergi
nutrit
supplement
avail
use
pediatr
popul
formula
contain
kcalml
kcal
ml
differ
carbohydr
fat
protein
content
palat
electrolyt
solut
load
patient
famili
understand
supplement
design
sourc
nutrit
patient
child
poor
appetit
refus
aliment
medic
caus
oral
ulcer
esophag
rule
physician
two
option
tube
feed
appetit
stimul
nasogastr
tube
feed
easi
technic
standpoint
may
increas
risk
sinu
infect
gastroesophag
reflux
older
children
may
affect
selfesteem
gastrostomi
tube
although
requir
surgic
placement
easi
manag
pose
cosmet
problem
increas
risk
author
experi
tube
place
signific
deterior
immun
nutrit
statu
occur
wound
heal
may
compromis
two
immunosuppress
children
care
author
institut
delay
heal
tissu
around
gastrostomi
site
requir
month
support
therapi
final
close
spontan
author
recommend
start
infus
formula
overnight
low
rate
slowli
increas
volum
vomit
develop
tube
may
advanc
jejunum
bypass
stomach
megestrol
acet
oral
administ
synthet
progest
agent
initi
use
increas
appetit
patient
cancer
product
promot
weight
gain
disadvantag
increas
fat
deposit
instead
lean
bodi
mass
thu
alter
bodi
habitu
uncontrol
studi
megestrol
acet
small
number
hivinfect
children
demonstr
weight
gain
side
effect
usual
dosag
mgkgd
divid
two
dose
recombin
growth
hormon
increas
lean
bodi
mass
adult
hiv
infect
anemia
patient
hiv
multifactori
common
caus
includ
nutrit
defici
iron
folic
acid
less
commonli
vitamin
bli
immun
hemolysi
hemorrhag
drug
toxic
bone
marrow
suppress
caus
hiv
viru
infecti
agent
malign
workup
anem
patient
includ
complet
blood
count
reticulocyt
count
iron
level
total
ironbind
capac
transferrin
level
vitamin
b
level
folic
acid
level
erythropoietin
level
sometim
lead
level
indic
hemolysi
suspect
coomb
test
perform
haptoglobin
level
obtain
algorithm
manag
anemia
present
figur
anemia
absent
reticulocyt
common
secondari
iron
defici
iron
sulfat
mgkgd
element
iron
usual
suffici
correct
hemoglobin
level
sometim
solut
easi
erythropoietin
level
less
iul
trial
erythropoietin
ukg
dose
three
time
week
suggest
respons
usual
occur
week
therapi
respons
unsatisfactori
higher
dose
may
given
usual
side
effect
bone
pain
polycythemia
patient
receiv
erythropoietin
alway
receiv
iron
supplement
increas
util
iron
hand
erythropoietin
iu
l
evid
iron
vitamin
folic
acid
defici
present
patient
reticulocytopen
altern
diagnos
need
investig
parvoviru
infect
caus
aplast
anemia
low
absent
reticulocyt
count
normal
high
erythropoietin
level
infect
confirm
iv
immunoglobulin
ivig
gkgdose
day
administ
respons
usual
rapid
result
increas
reticulocyt
hemoglobin
level
need
transfus
initi
therapi
follow
monthli
dose
g
mgkgdose
author
limit
experi
ivig
discontinu
relaps
aplast
anemia
may
occur
case
report
parvoviru
anemia
antiretrovir
therapyna
patient
show
resolut
anemia
initi
haart
anoth
common
opportunist
infect
caus
bone
marrow
suppr
figur
sion
anemia
dissemin
infect
mycobacterium
avium
complex
mac
infect
specif
caus
anemia
elucid
bone
marrow
aspir
may
necessari
megaloblast
chang
erythrocyt
may
result
antiretrovir
therapi
ie
zdv
stavudin
zalcitabin
macrocytosi
develop
within
week
commenc
therapi
antiretrovir
mean
corpuscular
volum
cellsml
level
vitamin
folic
acid
usual
within
normal
limit
instanc
intervent
need
anemia
associ
antiretrovir
use
option
decreas
dose
antiretrovir
agent
caus
anemia
elimin
drug
chang
treatment
regimen
megaloblast
anemia
also
caus
malabsorpt
poor
nutrit
level
folic
acid
vitamin
b
diminish
e
anemia
must
reevalu
appropri
supplement
provid
anemia
increas
reticulocyt
count
secondari
hemorrhag
hemolysi
decreas
level
haptoglobin
character
hemolysi
treatment
type
anemia
causespecif
beyond
scope
articl
neutropenia
defin
absolut
neutrophil
count
less
cellsml
common
find
hivinfect
children
may
occur
secondari
infect
nutrit
defici
drug
toxic
drug
use
treat
hiv
infect
zdv
tmpsmx
associ
develop
neutropenia
case
neutropenia
respond
initi
chang
antiretrovir
therapi
absolut
neutrophil
count
less
cellsml
trial
granulocyt
colonystimul
factor
start
kgdose
begun
granulocyt
colonystimul
factor
cytokin
increas
circul
neutrophil
improv
function
unlik
erythropoietin
respons
granulocyt
colonystimul
factor
immedi
demargin
leukocyt
dose
titrat
maintain
absolut
neutrophil
count
cellsml
thrombocytopenia
common
problem
among
hivinfect
children
may
occur
absenc
symptom
patient
initi
present
ill
although
specif
caus
usual
found
invetig
antibodi
platelet
glycoprotein
identifi
hivinfect
patient
thrombocytopenia
intervent
requir
especi
platelet
count
exce
plateletsml
case
thrombocytopenia
respond
initi
chang
antiretrovir
therapi
zdv
shown
benefici
treatment
patient
role
antiretrovir
agent
less
clear
platelet
count
less
plateletsml
bleed
present
treatment
institut
platelet
shortliv
cell
transfus
platelet
even
shorter
life
span
use
platelet
transfus
reserv
patient
activ
bleed
ivig
benefici
treatment
immun
thrombocytopenia
total
g
kg
administ
day
respons
wig
occur
given
intervalslo
patient
maintain
normal
platelet
count
month
interv
dose
increas
treatment
eventu
discontinu
rho
immun
globulin
intraven
winrho
sdf
altern
wig
hemolysi
may
result
signific
side
effect
corticosteroid
anoth
altern
treatment
prednison
usual
start
dose
mg
kgl
week
taper
discontinu
thrombocytopenia
may
relaps
steroid
discontinu
interferon
alfa
report
effect
patient
sever
thrombocytopenia
resist
antiretrovir
therapi
splenectomi
option
consid
treatment
fail
usual
result
resolut
thrombocytopenia
lack
spleen
predispos
children
encapsul
bacteri
splenectomi
consid
children
immun
pneumococc
haemophilu
influenza
type
b
meningococc
vaccin
new
approach
use
recombin
thrombopoietin
harker
et
experiment
treat
three
chimpanze
infect
hiv
thrombocytopenia
pegyl
recombin
human
megakaryocyt
growth
develop
factor
chimpanze
tenfold
increas
platelet
number
increas
marrow
megakaryocyt
number
fourfold
increas
marrow
megakaryocyt
progenitor
cell
hand
cole
et
p
found
thrombocytopenia
hninfect
patient
caus
shorten
platelet
life
span
increas
splenic
sequestr
ineffect
deliveri
viabl
platelet
level
thrombopoietin
significantli
higher
control
eventu
role
agent
treatment
thrombocytopenia
children
adult
infect
hiv
unclear
occurr
ulcer
oral
caviti
present
diagnost
dilemma
viral
infect
hsv
cmv
coxsacki
infect
well
bacteria
may
caus
agent
biopsi
cultur
lesion
persist
increas
size
number
recommend
cultur
test
viral
bacteri
aerob
anaerob
cultur
mycobacteri
fungal
infect
result
neg
biopsi
diagnost
author
assum
aphthou
ulcer
treat
patient
accordingli
aphthou
lesion
may
occur
posterior
pharynx
esophagu
perirect
area
vulva
treatment
ulcer
trial
error
aphthou
ulcer
typic
occur
sever
immunosuppress
patient
treatment
oral
aphtha
mixtur
viscou
lidocain
antacid
maalox
diphenhydramin
mycostatin
swish
swallow
may
reliev
symptom
altern
treatment
use
clindamycin
steroid
perirect
vulvar
lesion
commonli
respond
mixtur
equal
part
aquaphor
beiersdorf
norwalk
ct
cholestyramin
one
case
author
institut
fever
weight
loss
oral
ulcer
develop
immunosuppress
old
male
adolesc
cultur
grew
cmv
patient
respond
well
treatment
ganciclovir
resolut
symptom
altern
cimetidin
chlorhexidin
system
steroid
case
esophag
diagnos
clinic
symptom
confirm
barium
swallow
studi
case
treatment
begun
empir
candida
esophag
especi
presenc
oral
candidiasi
fluconazol
drug
choic
given
dose
mgkgd
one
daili
dose
choic
inpati
versu
outpati
treatment
depend
hydrat
clinic
condit
patient
reliabl
caregiv
patient
respond
empir
treatment
day
endoscopi
biopsi
cultur
esophag
mucosa
done
biopsi
result
compat
fungal
infect
parenter
amphotericin
b
drug
choic
candida
albican
torulopsi
glabrata
candida
krusei
resist
fluconazol
patient
receiv
recurr
cours
prophylact
regimen
fluconazol
risk
resist
infect
difficulttotreat
case
therapi
guid
antifung
suscept
children
recurr
sever
oral
thrush
develop
resist
antifung
manag
author
center
iv
amphotericin
b
infus
two
three
time
week
control
pain
infect
esophag
secondari
hsv
treat
iv
acyclovir
divid
three
dose
cmv
caus
iv
ganciclovir
use
sometim
caus
esophag
uncertain
even
biopsi
manag
patient
iscontroversi
option
discuss
treatment
aphthou
ulcer
appli
patient
recurr
esophag
risk
esophag
stenosi
develop
chronic
bilater
enlarg
parotid
gland
may
occur
mani
children
hiv
infect
usual
requir
treatment
sometim
parotid
pain
fever
develop
patient
instanc
infect
suspect
frequent
staphylococcu
aureu
although
mouth
flora
may
also
present
complic
easili
manag
cours
oral
antibiot
use
antistaphylococc
agent
rare
occas
suppur
suspect
otolaryngologist
consult
evalu
need
surgic
treatment
lymphoma
tumor
includ
differenti
diagnosi
especi
children
increas
parotid
sue
diarrhea
common
manifest
hiv
infect
although
infecti
caus
frequent
suspect
import
caus
includ
side
effect
medic
malign
hiv
enteropathi
antibacteri
agent
indic
treatment
diarrhea
associ
enter
pathogen
shigella
salmonella
campylobact
adult
patient
commonli
improv
fluoroquinolon
children
altern
eg
ampicillin
thirdgener
cephalosporin
tmpsmx
use
hivinfect
patient
especi
low
cell
count
frequent
exposur
antibiot
risk
diarrhea
caus
clostridium
dificil
treatment
choic
metronidazol
oral
administ
vancomycin
use
altern
drug
relaps
consid
treatment
failur
mani
patient
relaps
patient
retreat
metronidazol
mani
virus
includ
rotaviru
caliciviru
adenoviru
coronaviru
astroviru
caus
diarrhea
specif
treatment
avail
coliti
associ
cmv
ganciclovir
hsv
acyclovir
manag
parasit
mycobacteri
infect
discuss
section
opportunist
infect
pathogen
identifi
consult
pediatr
gastroenterologist
indic
possibl
endoscopi
biopsi
children
immunosuppress
high
viral
load
benefit
haart
antiretrovir
may
caus
diarrhea
one
seri
patient
receiv
proteas
inhibitor
diarrhea
patient
specif
caus
diarrhea
identifi
may
benefit
lactosefre
diet
abdomin
distens
without
diarrhea
anoth
common
find
hivinfect
children
children
without
diarrhea
enlarg
liver
spleen
may
account
distens
patient
diarrhea
bacteri
overgrowth
upper
gastrointestin
tract
suspect
distens
worsen
meal
breath
test
abnorm
even
challeng
carbohydr
cultur
gastric
duoden
fluid
commonli
posit
stomach
ph
decreas
acid
treatment
consist
metronidazol
mgkgd
divid
dose
day
expert
suggest
use
lactobacillu
restor
normal
bowel
flora
lymphoid
interstiti
pneumon
chronic
lymphocyt
infiltr
diseas
diagnosi
lip
children
usual
base
typic
chest
radiograph
persist
reticulondular
bilater
infiltr
sever
case
signific
club
occur
asymptomat
children
lip
normal
oxygen
satur
chest
radiograph
obtain
least
year
oxygen
satur
monitor
use
puls
oxymetri
clinic
visit
patient
hypox
steroid
indic
prednison
given
dose
mgkgd
week
subsequ
taper
mg
kgd
therapi
continu
oxygen
satur
becom
normal
children
respond
treatment
within
first
week
gener
adequ
respons
occur
steroid
may
wean
discontinu
case
repeat
cours
steroid
may
warrant
children
sever
advanc
lung
diseas
may
respond
steroid
therapi
respons
occur
month
steroid
discontinu
addit
bronchodil
chest
physic
therapi
help
adjunct
therapi
use
low
dose
diuret
may
also
improv
respiratori
statu
deal
suspect
bacteri
pneumonia
aggress
approach
taken
patient
chronic
lung
diseas
possibl
treatment
direct
specif
pathogen
caus
infect
treatment
usual
empir
noninvas
diagnost
procedur
blood
sputum
cultur
yield
organ
approxim
case
therapi
direct
usual
pathogen
ie
streptococcu
pneumonia
h
infuenza
staphylococcu
aureu
patient
chronic
lung
diseas
gramneg
organ
especi
p
aeruginosa
must
consid
potenti
pathogen
author
good
experi
combin
ticarcillinclavulan
acid
addit
aminoglycosid
consid
immunocompromis
patient
infect
resist
strain
gramneg
rod
aminoglycosid
deliv
nebul
tobramycin
mg
three
time
day
decreas
risk
nephrotox
improv
deliveri
affect
area
patient
improv
condit
deterior
treatment
bronchoalveolar
lavag
indic
diagnosi
length
therapi
depend
caus
sever
ill
although
author
usual
recommend
day
system
antibiot
therapi
children
benefit
longer
cours
treatment
patient
chronic
lung
diseas
pulmonari
function
test
may
benefici
onset
treatment
use
indic
length
therapi
pulmonari
function
test
continu
improv
day
antibiot
therapi
treatment
continu
return
baselin
new
plateau
reach
children
hiv
infect
bronchiectasi
frequent
episod
bacteri
pneumonia
may
benefit
daili
prophylaxi
tmpsmx
success
decreas
e
frequenc
infect
monthli
infus
ivig
mgkgd
may
benefici
hivassoci
nephropathi
children
present
spectrum
diseas
rang
mild
moder
proteinuria
persist
hematuria
renal
tubular
acidosi
endstag
renal
diseas
esrd
time
urin
collect
difficult
perform
children
author
use
ratio
urin
creatinin
urin
protein
calcul
degre
proteinuria
normal
creatineprotein
ratio
less
ratio
abnorm
consist
nephrot
rang
proteinuria
find
persist
lead
hypoalbuminemia
edema
without
elev
serum
triglycerid
occur
patient
idiopath
nephrot
syndrom
renal
function
deterior
slowli
children
adult
renal
sonographi
show
increas
echogen
provid
detail
b
c
n
kidney
biopsi
kidney
usual
show
focal
segment
glomerulosclerosi
diffus
mesangi
hyperplasia
less
frequent
minim
chang
system
lupu
erythematouslik
nephropathi
renal
tubular
acidosi
correct
alkalin
agent
author
use
sodium
potassium
citrat
depend
electrolyt
abnorm
one
milliequival
citrat
equival
one
milliequival
bicarbon
author
start
meqkgd
divid
dose
adjust
dose
maintain
normal
serum
ph
patient
renal
tubular
acidosi
may
also
need
supplement
miner
calcium
magnesium
phosphoru
therapi
patient
proteinuria
divid
two
categori
treatment
incipi
renal
diseas
slow
progress
esrd
treatment
esrd
progress
diseas
children
rapid
adult
first
approach
observ
patient
period
time
monitor
electrolyt
blood
urea
nitrogen
bun
creatinin
drug
commonli
use
hiv
infect
need
dose
modif
patient
renal
impair
includ
use
nephrotox
agent
avoid
sinc
pathogenesi
diseas
link
immun
complex
deposit
initi
approach
use
immunosuppress
agent
steroid
repres
anoth
option
sever
studi
suggest
glucocorticoid
might
slow
progress
hivassoci
nephropathi
use
steroid
children
benefici
adult
diabet
patient
proteinuria
benefit
treatment
angiotensinconvert
enzym
inhibitor
kimmel
et
compar
progress
renal
insuffici
esrd
patient
biopsyproven
hivassoci
nephropathi
nine
patient
treat
captopril
nine
patient
receiv
angiotensinconvert
enzym
inhibitor
mean
surviv
renal
function
captopril
group
day
versu
day
control
group
gorriz
et
describ
white
homosexu
man
infect
nephrot
rang
proteinuria
success
treat
proteinuria
may
persist
long
period
without
progress
pediatr
patient
author
usual
elect
follow
patient
without
specif
treatment
long
remain
asymptomat
everi
manifest
hiv
infect
haart
may
sigrufic
role
prevent
treatment
nephrpathi
esrd
develop
decis
regard
dialysi
must
made
avail
haart
improv
prognosi
extend
surviv
time
mandat
aggress
approach
univers
miami
sever
children
hivassoci
nephropathi
receiv
longterm
periton
dialysi
manag
conjunct
pediatr
nephrolog
team
cardiac
involv
aid
first
report
woman
kaposi
sarcoma
involv
anterior
cardiac
wall
sinc
multipl
report
discuss
incid
etiolog
manifest
manag
spectrum
cardiac
diseas
rang
clinic
silent
lesion
fatal
diseas
sever
diseas
correl
degre
immun
suppress
cardiomyopathi
seem
affect
surviv
hivinfect
autopsi
studi
hivinfect
adult
indic
mani
dilat
cardiomyopathi
mani
myocard
death
depress
left
ventricular
function
common
progress
children
serial
studi
children
advanc
symptomat
hiv
infect
show
decreas
left
ventricular
function
ventricular
dilat
everi
structur
heart
cardiac
lesion
describ
patient
hiv
includ
pericardi
effus
pericard
myocard
dilat
cardiomyopathi
endocard
vascular
lesion
aneurysm
atherosclerosi
pulmonari
hypertens
infiltr
neoplasm
ie
kaposi
sarcoma
lymphoma
also
report
caus
cardiomyopathi
multifactori
hiv
found
heart
whether
role
pathogenesi
relat
direct
effect
myocardium
secondari
immun
respons
matter
controversi
factor
could
involv
pathogenesi
cardiomyopathi
includ
infect
coxsacki
b
viru
cmv
epsteinbarr
viru
toxoplasma
opportunist
infect
pulmonari
diseas
wast
nutrit
defici
ie
selenium
camipharmacotherapeut
agent
ie
antiretrovir
pentamidin
amphotericin
b
foscarnet
interferon
alfa
tmpsmx
steroid
illicit
drug
hiv
cardiomyopathi
start
earli
life
multicent
studi
lung
cardiac
patholog
hivinfect
patient
fetal
echocardiographi
perform
fetus
hivinfect
mother
fetus
hivinfect
mother
increas
right
left
ventricular
wall
thick
decreas
heart
rate
increas
right
left
ventricular
outflow
veloc
postnat
phase
studi
show
increas
preval
structur
heart
diseas
signific
differ
preval
congenit
cardiovascular
malform
found
among
hivinfect
noninfect
studi
show
lower
preval
routin
use
echocardiogram
children
hiv
greatli
influenc
report
preval
hiv
cardiomyopathi
common
clinic
manifest
cardiomyopathi
sinu
tachyardi
associ
manifest
includ
bradycardia
dysrhythmia
abnorm
blood
pressur
ie
hypotens
hypertens
left
ventricular
hypertrophi
pulmonari
hypertens
pericardi
effus
congest
heart
failur
chf
evalu
cardiac
statu
includ
thorough
histori
physic
examin
follow
specif
diagnost
test
clinic
indic
initi
test
includ
chest
radiographi
ecg
chest
radiographi
use
evalu
heart
size
presenc
pulmonari
diseas
eg
lip
pneumonia
pleural
effus
intrathorac
abnorm
patient
examin
ecg
autopsi
cardiac
abnorm
detect
often
expect
physic
examin
rais
question
whether
ecg
part
routin
examin
hivinfect
children
especi
low
cell
count
l
p
hl
z
prospect
follow
hivinfect
children
baselin
ecg
enrol
everi
month
thereaft
year
found
subclin
cardiac
abnorm
common
also
persist
often
progress
similar
data
avail
hivinfect
adult
although
introduc
ecg
part
routin
care
hivinfect
children
impli
signific
cost
addit
workload
period
ecg
assess
may
benefici
center
recommend
annual
ecg
asymptomat
patient
everi
month
symptomat
test
use
assess
cardiomyopathi
includ
holter
monitor
rare
cardiac
catheter
endomyocardi
biopsi
noncardiac
predictor
hemodynam
abnorm
aid
wast
lip
recurr
bacteri
infect
encephalopathi
anemia
posit
cmv
epsteinbarr
viru
serolog
age
less
year
treatment
hiv
cardiomyopathi
start
earli
detect
specif
therapi
infecti
caus
hivassoci
heart
diseas
cmv
mycobacterium
avium
complex
diseas
tuberculosi
toxoplasmosi
salmonellosi
signific
effect
outcom
problem
anemia
nutrit
defici
hypoxemia
electrolyt
defici
need
correct
nonpharmaceut
therapeut
measur
includ
limit
physic
activ
restrict
salt
fluid
intak
oxygen
pharmacolog
treatment
done
step
mildest
manifest
chf
treat
angiotensinconvert
enzym
inhibitor
two
commonli
use
agent
enalapril
captopril
clinician
favor
enalapril
advantag
onceor
twiceaday
administr
although
manufactur
specifi
pediatr
dose
two
studi
start
patient
mgkgd
titrat
upward
toler
maximum
mgkgd
renal
function
serum
electrolyt
blood
pressur
must
monitor
close
use
class
drug
next
step
diuret
loop
diuret
eg
furosemid
prefer
thiazid
less
potent
effici
decreas
decreas
glomerular
filtrat
rate
patient
remain
symptomat
despit
measur
may
benefit
use
digoxin
antihypertens
antiarrhythm
agent
prescrib
appropri
conjunct
pediatr
cardiologist
ivig
report
effect
patient
kawasaki
syndrom
chf
refractori
anticongest
therapi
acut
myocard
one
studi
hivinfect
chldren
monthli
infus
ivig
seem
better
left
ventricular
function
anecdot
report
recommend
use
steroid
immun
suppressor
agent
manag
patient
cardiomyopathi
interferon
alfa
also
associ
improv
myocardi
dysfunct
hivinfect
pericardi
effus
usual
incident
ecg
find
treatment
depend
sever
caus
tamponad
present
pericardiocentesi
necessari
pericardiocentesi
also
indic
bacteri
infect
suspect
nonsteroid
antiinflammatori
agent
use
manag
patient
pain
steroid
recommend
anoth
issu
manag
patient
hypercholesterolemia
hypertriglyceridemia
secondari
use
proteas
inhibitor
adult
issu
whether
proteas
inhibitor
caus
coronari
arteri
diseas
far
pediatr
earli
coronari
arteri
diseas
report
hyperlipidemia
lipodystrophi
insulinresist
diabet
mellitu
coronari
arteri
diseas
report
adult
recommend
treatment
side
effect
modif
diet
pharmacolog
treatment
lipidlow
agent
necessari
expert
recommend
discontinu
proteas
inhibitor
measur
progress
static
encephalopathi
cognit
behavior
motor
manifest
describ
hivinfect
although
children
neurolog
impair
identifi
pathogen
hiv
encephalopathi
may
occur
result
opportunist
infect
inflammatori
diseas
vascular
diseas
neoplast
chang
evid
show
hiv
infect
cn
associ
typic
neuropatholog
accord
center
diseas
control
prevent
cdc
revis
classif
diagnosi
encephalopathi
requir
one
follow
progress
find
present
least
month
absenc
identifi
caus
failur
attain
loss
development
mileston
loss
intellectu
abil
verifi
standard
development
scale
neuropsycholog
test
impair
brain
growth
acquir
microcephali
demonstr
head
circumfer
measur
brain
atrophi
demonstr
ct
mr
imag
serial
imag
requir
children
less
year
age
acquir
symmetr
motor
deficit
manifest
two
follow
paresi
patholog
reflex
ataxia
gait
disturb
estim
preval
hivrel
encephalopathi
children
much
lower
report
first
decad
pediatr
aid
epidem
woman
infant
transmiss
studi
prospect
follow
hivinfect
children
children
diagnos
hiv
encephalopathi
encephalopathi
common
advanc
diseas
children
categori
b
c
categori
presenc
encephalopathi
increas
risk
death
presenc
hepatomegali
splenomegali
lymphadenopathi
first
month
life
increas
viral
load
correl
presenc
encephalopathi
trend
although
statist
signific
show
children
posit
hiv
cultur
first
week
life
higher
risk
encephalopathi
level
hiv
rna
cerebrospin
fluid
may
import
predictor
encephalopathi
encephalopathi
hivinfect
children
secondari
hiv
intercurr
ill
infect
pathogen
neoplasm
vascular
inflammatori
diseas
workup
children
hiv
encephalopathi
follow
evalu
pediatr
neurologist
development
audiolog
ophthalmolog
evalu
imag
brain
ct
r
imag
cerebr
atrophi
attenu
white
matter
cerebr
calcif
common
find
ct
scan
easili
detect
calcif
mr
imag
superior
detect
whitematt
abnorm
atrophi
valu
monitor
hiv
rna
viral
load
cerebrospin
fluid
yet
well
specif
test
expect
pathogen
ie
cryptococcu
neoforman
toxoplasma
gondii
mycobacterium
tuberculosi
nontuberculosi
cmv
hsv
varicella
zoster
viru
treponema
pallidum
appropri
treatment
identifi
caus
caus
hiv
identifi
treatment
goal
reduc
viral
load
antiretrovir
penetr
across
bloodbrain
barrier
zdv
stavudin
nevirapin
although
proteas
inhibitor
may
good
csf
penetr
high
protein
bind
one
small
studi
use
r
imag
brain
studi
demonstr
improv
progress
white
matter
diseas
adult
patient
proteas
inhibitor
versu
worsen
patient
use
agent
depend
sever
diseas
patient
encephalopathi
need
strong
support
system
physic
therapi
brace
even
surgeri
sometim
necessari
minim
contractur
baclofen
role
treatment
hyperton
seizur
treat
antiepilept
agent
conjunct
neurologist
patient
may
decreas
appetit
may
problem
swallow
feed
tube
may
need
hivinfect
children
similar
immun
schedul
hivnoninfect
children
tabl
except
variat
discuss
section
administr
vaccin
led
transient
increas
hiv
viral
load
effect
contraind
use
vaccinesl
seri
three
dose
inactiv
polio
vaccin
month
age
follow
booster
dose
year
recommend
children
hiv
infect
risk
infect
resid
household
immunocompromis
host
receiv
oral
polio
vaccin
vaccin
viru
shed
gastrointestin
tract
could
caus
vaccineassoci
paralyt
poliomyel
suscept
host
earli
year
aid
epidem
infect
children
unit
state
receiv
primari
booster
dose
oral
polio
vaccin
without
complic
develop
countri
oral
polio
vaccin
continu
administ
inactiv
polio
vaccin
readili
avail
theoret
risk
vaccineassoci
paralyt
poliomyel
exist
recommend
vaccin
unit
state
measlesmumpsrubella
vaccin
live
attenu
viral
vaccin
given
month
age
booster
dose
year
age
area
high
preval
measl
exist
monoval
measl
vaccin
given
month
age
earli
year
aid
epidem
children
hiv
develop
measl
infect
high
risk
complic
death
suggest
benefit
administ
live
viral
vaccin
outweigh
potenti
risk
one
case
report
hemophiliac
man
infect
hiv
immun
measlesmumpsrubella
vaccin
giant
cell
pneumonia
develop
year
later
patient
measl
vaccin
viru
isol
postmortem
specimen
sinc
report
recommend
alter
children
mild
moder
immunosuppress
ie
immun
categori
receiv
measl
vaccin
children
sever
immunosuppress
ie
immun
categori
exclud
whether
child
sever
immunosuppress
respond
haart
increas
tcell
count
percentag
correspond
immun
categori
immun
measl
vaccin
matter
controversi
time
function
capac
cell
restor
uncertain
reliabl
quantit
test
avail
defin
function
restor
cell
immun
measl
vaccin
recommend
situat
also
antibodi
respons
measl
vaccin
hivinfect
children
may
vari
amount
durat
depend
clinic
immun
statu
children
case
exposur
measl
hivinfect
children
receiv
prophylaxi
immunoglobulin
prefer
within
hour
exposur
dose
recommend
children
symptomat
hiv
infect
mlkg
maximum
dose
ml
asymptomat
children
ml
kg
given
intramuscularli
children
receiv
ivig
therapi
within
week
exposur
need
addit
prophylaxi
yearli
influenza
vaccin
recommend
infant
children
hiv
infect
month
age
older
subvirion
splitviru
vaccin
use
children
less
year
age
minim
fever
advers
side
effect
children
less
year
age
immun
previous
receiv
two
dose
vaccin
given
month
apart
children
previous
immun
vaccin
one
dose
adequ
physician
review
offici
recommend
influenza
vaccin
yearli
composit
vaccin
vari
dosag
children
age
year
less
may
differ
older
children
vaccin
given
earli
autumn
onset
flu
season
addit
household
contact
highrisk
children
also
immun
incid
infect
streptococcu
pneumonia
increas
hivinfect
children
addit
organ
increas
pattern
resist
penicillin
cephalosporin
current
avail
polyval
pneumococc
polysaccharid
vaccin
given
hivinfect
children
age
year
older
booster
dose
recommend
year
new
proteinconjug
heptaval
pneumococc
vaccin
develop
show
safeti
immunogen
reduc
incid
otiti
media
invas
diseas
secondari
pneumonia
infect
normal
infant
cluldren
limit
inform
use
vaccin
hivinfect
children
avail
varicella
infect
associ
increas
morbid
children
hiv
infect
children
sever
immunocomprom
recurr
herp
zoster
viru
chronic
varicella
infect
may
develop
advisori
committe
immun
practic
recommend
administ
varicella
vaccin
person
cellular
immun
defici
increas
risk
morbid
varicella
herp
zoster
advisori
committe
immun
practic
recommend
varicella
vaccin
consid
children
asymptomat
mildli
symptomat
hiv
infect
cdc
classif
al
agespecif
tlymphocyt
percentag
vaccin
administ
two
dose
interv
dose
group
children
schedul
differ
vaccin
schedul
healthi
children
strongli
recommend
hivneg
sibl
children
live
household
hivinfect
adult
children
vaccin
administ
children
hiv
infect
moder
sever
immunocomprom
studi
evalu
safeti
toler
vaccin
hivinfect
children
ongo
studyto
determin
safeti
immunogen
oka
strain
varicella
vaccin
hivinfect
children
age
year
stage
al
histori
varicella
infect
neg
titer
receiv
two
dose
vaccin
separ
month
sever
advers
effect
report
fever
occur
recipi
first
dose
second
dose
local
reaction
similar
seen
healthi
children
eight
exposur
one
mild
case
varicella
occur
varicellazost
viru
antibodi
specif
lymphocyt
prolifer
respect
detect
patient
first
patient
second
dose
suscept
children
hiv
infect
expos
varicella
receiv
passiv
immun
varicellazost
immunoglobulin
given
within
hour
exposur
child
receiv
ivig
within
week
exposur
varicellazost
immunoglobulin
necessari
hepat
b
diphtheria
pertussi
tetanu
h
influenm
type
b
vaccin
recommend
hivinfect
noninfect
children
bacillu
calmetteguerin
vaccin
live
attenu
vaccin
contraind
children
hiv
live
unit
state
world
health
organ
continu
recommend
administr
vaccin
birth
countri
high
preval
tuberculosi
even
mother
known
hiv
infect
rotaviru
vaccin
evalu
hivinfect
children
recommend
use
popul
wise
physician
said
medicin
give
year
life
life
year
qualiti
life
import
issu
deal
chronic
ill
patient
especi
late
stage
hiv
infect
palli
medicin
focus
manag
physic
psycholog
social
aspect
inher
ultim
lethal
diseas
children
hiv
infect
may
experi
pain
ill
medic
surgic
procedur
done
allevi
ill
aggress
approach
pain
manag
children
hiv
infect
recommend
success
therapi
determin
selfreport
children
use
agespecif
scale
type
dose
medic
use
depend
degre
pain
experienc
tabl
certain
principl
appli
pain
manag
opioid
therapi
safe
infant
children
therapi
individu
aroundtheclock
therapi
prefer
intermitt
dose
intramuscular
subcutan
rout
avoid
oral
iv
rout
prefer
use
behavior
techniqu
also
signific
begin
open
sincer
relationship
exist
physician
patient
patient
famili
possibl
pediatr
patient
involv
decis
make
involv
minim
care
pain
manag
physician
believ
therapi
would
futil
suffer
would
great
issu
resuscit
discuss
patient
famili
physician
may
difficulti
determin
right
time
bring
issu
convers
preced
situat
patient
requir
artifici
life
suppw
whether
includ
children
decis
make
depend
child
age
matur
famili
prefer
psychiatr
evalu
may
help
assess
level
matur
patient
referr
hospic
termin
care
facil
appropri
provid
support
famili
difficult
time
children
perinat
acquir
hiv
surviv
longer
begin
pediatr
aid
epidem
children
enter
late
childhood
adolesc
awar
diagnos
children
chronic
diseas
know
diagnos
shown
cope
better
ill
know
diagnos
past
year
famili
afraid
tell
children
hiv
infect
fear
children
disclos
other
famili
would
stigmat
denial
guilt
transmit
infect
children
ongo
dialogu
famili
regard
import
disclosur
import
age
matur
social
circumst
children
must
taken
consider
disclosur
done
languag
level
children
understand
neuropsycholog
test
guid
practition
determin
development
age
child
simpl
uncompl
explan
given
children
year
age
older
children
adolesc
full
disclosur
convey
understand
infect
transmit
protect
other
get
infect
sens
respons
health
children
becom
activ
particip
health
care
children
reach
adolesc
issu
complianc
aris
teenag
abl
express
opinion
type
medic
regimen
accommod
full
realiz
consequ
take
medic
disclosur
may
occur
famili
guardian
child
assist
physician
social
worker
counsel
session
includ
discuss
must
know
diagnosi
author
encourag
tell
sibl
matur
enough
handl
respons
know
inform
support
infect
child
physician
answer
question
openli
truth
prevent
misconcept
ill
subsequ
visit
physician
allow
children
ask
question
regard
diagnosi
disclosur
children
given
opportun
speak
anoth
infect
child
attend
peer
support
group
feel
isol
summari
signific
advanc
made
understand
pathophysiolog
hiv
infect
sinc
begin
epidem
h
knowledg
translat
develop
new
therapi
hiv
opportunist
infect
laboratori
advanc
monitor
viral
immun
statu
better
understand
factor
affect
patient
outcom
concomitantli
signific
progress
made
medic
manag
children
hiv
infect
past
year
number
children
report
aid
unit
state
decreas
effort
shift
care
children
advanc
immunosuppress
sever
opportunist
infect
earli
haart
mainten
immun
system
prevent
opportunist
infect
primari
care
physician
involv
inform
care
hivinfect
patient
although
publish
data
limit
physician
work
popul
observ
dramat
improv
qualiti
life
length
surviv
patient
unfortun
progress
share
develop
countri
resourc
minim
antiretrovir
agent
commonli
unavail
although
effort
develop
vaccin
prevent
hiv
infect
ongo
progress
slow
educ
awar
continu
power
weapon
hiv
